Collaboration and License Agreement with Genentech, Inc.	6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and License Agreement with Genentech, Inc.	8. Collaboration and License Agreement with Genentech, Inc. In December 2020, the Company and Genentech, Inc. (“Genentech”) entered into the Collaboration and License Agreement (“Genentech Agreement”). During the three and six months ended June 30, 2023 and 2022, there were no material changes to the Genentech Agreement. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2023. During the three months ended June 30, 2023 and 2022, the Company recognized $0.1 million and $0.3 million of revenue, respectively, from the Genentech Agreement. During the six months ended June 30, 2023 and 2022, the Company recognized $0.3 million and $0.5 million of revenue, respectively, from the Genentech Agreement. As of December 31, 2022, the Company recorded a contract asset of $4.9 million, which was classified as a current asset on the condensed consolidated balance sheet. The contract asset related to the amount of revenue recognized for which the right to payment was contingent upon conditions other than the passage of time, such as the completion of future milestone activities. During the three months ended June 30, 2023, such conditions were satisfied and $5.0 million was paid in cash to the Company, at which point the contract asset was eliminated. As of June 30, 2023, less than $0.1 million from such payment was recorded as deferred revenue within current liabilities on the condensed consolidated balance sheet. As of June 30, 2023 and December 31, 2022, the Company recorded an other liability of $25.0 million, representing the amount of certain development milestones achieved as of such dates under the Genentech Agreement. The amounts have been excluded from the transaction price at both June 30, 2023 and December 31, 2022 and, therefore, excluded from amounts recognized as revenue to date, since they are subject to repayment to Genentech if the Company exercises its option to participate in the Profit/Cost Share under the Genentech Agreement.

Collaboration and License Agreement with Genentech, Inc.

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration and License Agreement with Genentech, Inc.

8. Collaboration and License Agreement with Genentech, Inc.

In December 2020, the Company and Genentech, Inc. (“Genentech”) entered into the Collaboration and License Agreement (“Genentech Agreement”). During the three and six months ended June 30, 2023 and 2022, there were no material changes to the Genentech Agreement. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2023.

During the three months ended June 30, 2023 and 2022, the Company recognized $0.1 million and $0.3 million of revenue, respectively, from the Genentech Agreement.

During the six months ended June 30, 2023 and 2022, the Company recognized $0.3 million and $0.5 million of revenue, respectively, from the Genentech Agreement.

As of December 31, 2022, the Company recorded a contract asset of $4.9 million, which was classified as a current asset on the condensed consolidated balance sheet. The contract asset related to the amount of revenue recognized for which the right to payment was contingent upon conditions other than the passage of time, such as the completion of future milestone activities. During the three months ended June 30, 2023, such conditions were satisfied and $5.0 million was paid in cash to the Company, at which point the contract asset was eliminated. As of June 30, 2023, less than $0.1 million from such payment was recorded as deferred revenue within current liabilities on the condensed consolidated balance sheet.

As of June 30, 2023 and December 31, 2022, the Company recorded an other liability of $25.0 million, representing the amount of certain development milestones achieved as of such dates under the Genentech Agreement. The amounts have been excluded from the transaction price at both June 30, 2023 and December 31, 2022 and, therefore, excluded from amounts recognized as revenue to date, since they are subject to repayment to Genentech if the Company exercises its option to participate in the Profit/Cost Share under the Genentech Agreement.